



Recent Advances
in Genitourinary
Malignancies



Hybrid Congress

6 February 2026

Auditorium PRBB

(Barcelona Biomedical Research Park)
C/ del Dr. Aiguader, 88, 08003 Barcelona

Directed by

Dr. Joaquim Bellmunt

Dr. Juan Pablo Fusco

www.ragm.es

Round Table 1
Prostatic Cancer



Round Table 2
Bladder Cancer



Round Table 3
Kidney Cancer

 **Hospital del Mar**
Research Institute[®]
Barcelona





Round Table 1
Prostatic Cancer

Program
08:30 – 10:10

08:30 – 08:45

Registration

08:45 – 09:00

Welcome and Opening

Dr. Joan Albanell

09:00 – 10:10

Moderator

Round Table 1: **Prostatic Cancer**

Lluís Fumadó Ciutat

09:00 – 09:05

Presentation

09:05 – 09:20

Treatment strategies for first line hormone sensitive prostate cancer

Dr. Jose Luis Pérez Gracia

09:20 – 09:35

**Expert opinion: The emerging role of parp inhibitors in combination in prostate cancer
Optimal therapeutic sequence in mCRPC**

Dr. Karim Fizazi

09:35 – 09:50

Novel Targeted and Therapeutic Strategies

Dr. J. M. Piulats

09:50 – 10:10

Discussion



Round Table 2
Bladder Cancer

Program
10:10 – 12:30

10:10 – 12:00

Moderator

Round Table 2: **Bladder Cancer**

Dr. Joaquim Bellmunt

10:10 – 10:15

Presentation

10:15 – 10:30

New treatment options in BCG naïve and refractory NMIBC

Dr. Félix Guerrero Ramos

10:30 – 10:45

New approaches in perioperative Muscle invasive Bladder Cancer

Dr. Begoña Pérez Valderrama

10:45 – 11:00

ct-DNA in urological malignancies

Dr. Thomas Powles

11:00 – 11:30

Controversies first Line options in Metastatic Bladder Cancer: What is next?

Dr. Álvaro Pinto (PRO)
& Dr. M^a José Juan Fita (CON)

11:30 – 12:00

Discussion

12:00 – 12:30

Coffee break

12:30 – 14:00
Moderator

Round Table 3: **Kidney Cancer**
Dr. Juan Pablo Fusco

12:30 – 12:35

Presentation

12:35 – 12:50

Adjuvant therapy in renal cell carcinoma
Dr. Jose Pablo Maroto

12:50 – 13:05

Relevant aspects to select the best sequence in first line including HIF2alpha inhibitors
Dr. Daniel Sentana

13:05 – 13:20

Management of variant histologies in RCC. New treatment options
Dr. Javier Puente

13:20 – 13:35

Cellular therapy in RCC
Dr. Elena Garralda

13:35 – 14:00

Discussion

14:00 – 14:20

Keynote lecture:
Ongoing clinical studies in prostate cancer
Neeraj Agarwall, MD, FASCO

14:20 – 14:30

Closing remarks
Dr. Joaquim Bellmunt & Dr. Juan Pablo Fusco

Joan Albanell

Head of the Medical Oncology Department Hospital del Mar.
Head of the Cancer Research Program. IMIM

Neeraj Agarwall

MD, FASCO, Professor of Medicine Senior Director for Clinical Research, Huntsman Cancer Institute (HCI) HCI Presidential Endowed Chair of Cancer Research Director, Center of Investigational Therapeutics Director, Genitourinary Oncology Program

Joaquim Bellmunt

Director of the Bladder Cancer Clinic of the Dana Farber Cancer Institute of Harvard in Boston (USA) IMIM de Senior Researcher

M^a José Juan Fita

Médico adjunto tumores urológicos. Instituto Valenciano de Oncología

Karim Fizazi

Medical oncologist at Centre Oscar Lambret and full professor in oncology at the University of Paris-Saclay, France

Lluís Fumadó

Urology and Kidney Trasplant Department. Head of Uro-Oncology Unit. Associate Professor. Researcher of the Cancer Research Program

Juan Pablo Fusco

Medical Oncology Deputy GenesisCare Spain. Medical Oncologist

Elena Garralda

Directora, Unidad de Investigación en Terapia molecular del Cáncer (UITM) — “CaixaResearch”

Felix Guerrero

Coordinator of the UroOncology Unit, Department of Urology, Hospital Universitario 12 de Octubre, Madrid. Head of the UroOncology Unit, ROC Clinic and HM Hospitales, Madrid

Pablo Maroto
Hospital San Pau

Jose Luis Pérez Gracia
Oncology Department. Clinica Universidad de Navarra

Begoña Pérez Valderrama
Hospital Virgen del Rocío, Sevilla, Spain

Álvaro Pinto
Coordinador de la Unidad de Tumores Urológicos, Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid. Profesor Asociado de Medicina, Universidad Autónoma, Madrid

J. M. Piulats
Oncólogo médico, Jefe sección GU, GYN, Sarcoma/Melanoma en el Institut Català d'Oncologia, Campus de Bellvitge. Jefe Grupo Inmunoterapia y Cancer en IDIBELL

Thomas Powles
MBBS, MRCP, Clinical Professor of Genitourinary Oncology (HCC) at Barts Cancer Institute, UK

Javier Puente
Institute of Oncology GU Cancer Unit Medical Oncology Department, Hospital Clínico San Carlos, Madrid

Daniel Sentana
Instructor in Medicine at the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute/Harvard Medical School

Scientific Organizer



Silver Sponsor



Bronze Sponsors



Contact

MeetingPharma
A/A Marina Rodríguez
mrodriguez@meetingpharma.com
www.meetingpharma.com

